Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab dose optimization after response in melanoma or renal cell carcinoma
NL-OMON54156Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in melanoma and renal cell carcinoma (RCC), sponsored by Erasmus MC. Primary endpoint: Difference in mean nivolumab trough level. Started Jan 2022; status: recruiting.
02
Drugs
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON54156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54156.